Danielle Wm Kemper1, Veronique Semjonow2, Femke de Theije2, Diederick Keizer2, Lian van Lippen2, Johannes Mair3, Bernadette Wille3, Michael Christ4, Felicitas Geier4, Pierre Hausfater5, David Pariente5, Volkher Scharnhorst6, Joyce Curvers6, Jeroen Nieuwenhuis2. 1. Philips Handheld Diagnostics, Eindhoven, The Netherlands. Electronic address: Danielle.Kemper@philips.com. 2. Philips Handheld Diagnostics, Eindhoven, The Netherlands. 3. Department of Internal Medicine III - Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Emergency and Critical Care Medicine, Paracelsus Medical University, Nuernberg General Hospital, Nuernberg, Germany. 5. Emergency Department, Hôpital Pitié-Salpêtrière, AP-HP et Sorbonne Universités UPMC Univ-Paris 06, France. 6. Clinical laboratory, Catharina Ziekenhuis Eindhoven and Technical University Eindhoven, Eindhoven, The Netherlands.
Abstract
OBJECTIVES: Point-of-care cardiac troponin testing with adequate analytical performances has the potential to improve chest pain patients flow in the emergency department. We present the analytical evaluation of the newly developed Philips Minicare cTnI point-of-care immunoassay. DESIGN & METHODS: Li-heparin whole blood and plasma were used to perform analytical studies. The sample type comparison study was performed at 4 different hospitals. The 99th percentile upper reference limit (URL) study was performed using Li-heparin plasma, Li-heparin whole blood and capillary blood samples from 750 healthy adults, aging from 18 to 86years. RESULTS: Limit of the blank, limit of detection and limit of quantitation at 20% coefficient of variation (CV) were determined to be 8.5ng/L, 18ng/L and 38ng/L respectively without significant differences between whole blood and plasma for LoQ. Cross-reactivity and interferences were minimal and no high-dose hook was observed. Total CV was found to be from 7.3% to 12% for cTnI concentrations between 109.6 and 6135.4ng/L. CV at the 99th percentile URL was 18.6%. The sample type comparison study between capillary blood, Li-heparin whole blood and Li-heparin plasma samples demonstrated correlation coefficients between 0.99 and 1.00 with slopes between 1.03 and 1.08. The method comparison between Minicare cTnI and Beckman Coulter Access, AccuTnI+3 demonstrated a correlation coefficient of 0.973 with a slope of 1.09. The 99th percentile URL of a healthy population was calculated to be 43ng/L with no significant difference between genders or sample types. CONCLUSIONS: The Minicare cTnI assay is a sensitive and precise, clinical usable test for determination of cTnI concentration that can be used in a near-patient setting as an aid in the diagnosis of acute myocardial infarction.
OBJECTIVES: Point-of-care cardiac troponin testing with adequate analytical performances has the potential to improve chest painpatients flow in the emergency department. We present the analytical evaluation of the newly developed Philips Minicare cTnI point-of-care immunoassay. DESIGN & METHODS:Li-heparin whole blood and plasma were used to perform analytical studies. The sample type comparison study was performed at 4 different hospitals. The 99th percentile upper reference limit (URL) study was performed using Li-heparin plasma, Li-heparin whole blood and capillary blood samples from 750 healthy adults, aging from 18 to 86years. RESULTS: Limit of the blank, limit of detection and limit of quantitation at 20% coefficient of variation (CV) were determined to be 8.5ng/L, 18ng/L and 38ng/L respectively without significant differences between whole blood and plasma for LoQ. Cross-reactivity and interferences were minimal and no high-dose hook was observed. Total CV was found to be from 7.3% to 12% for cTnI concentrations between 109.6 and 6135.4ng/L. CV at the 99th percentile URL was 18.6%. The sample type comparison study between capillary blood, Li-heparin whole blood and Li-heparin plasma samples demonstrated correlation coefficients between 0.99 and 1.00 with slopes between 1.03 and 1.08. The method comparison between Minicare cTnI and Beckman Coulter Access, AccuTnI+3 demonstrated a correlation coefficient of 0.973 with a slope of 1.09. The 99th percentile URL of a healthy population was calculated to be 43ng/L with no significant difference between genders or sample types. CONCLUSIONS: The Minicare cTnI assay is a sensitive and precise, clinical usable test for determination of cTnI concentration that can be used in a near-patient setting as an aid in the diagnosis of acute myocardial infarction.
Authors: Daniel Y Joh; Angus M Hucknall; Qingshan Wei; Kelly A Mason; Margaret L Lund; Cassio M Fontes; Ryan T Hill; Rebecca Blair; Zackary Zimmers; Rohan K Achar; Derek Tseng; Raluca Gordan; Michael Freemark; Aydogan Ozcan; Ashutosh Chilkoti Journal: Proc Natl Acad Sci U S A Date: 2017-08-07 Impact factor: 11.205
Authors: Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg Journal: Nat Rev Cardiol Date: 2017-04-06 Impact factor: 32.419
Authors: Roberta Pintus; Pier Paolo Bassareo; Angelica Dessì; Martino Deidda; Giuseppe Mercuro; Vassilios Fanos Journal: Biomed Res Int Date: 2017-07-03 Impact factor: 3.411
Authors: Alexander van Reenen; Mario Berger; Emmanuel Moreau; Edwin Bekx; Tom Bruinink; Danielle Kemper; Lian van Lippen; Jos Weusten; Anita Mrakovic; Etienne Michielsen; Joost Vissers; Femke de Theije; Jeroen Nieuwenhuis; Veronique Semjonow; Johannes Mair Journal: Pract Lab Med Date: 2019-03-17